Senti Biosciences, Inc. (SNTI)

NASDAQ: SNTI · Real-Time Price · USD

2.240

+0.080 (3.70%)

Nov 4, 2024, 4:00 PM EST - Market closed

Senti Biosciences Employees

Senti Biosciences had 48 employees as of December 31, 2023. The number of employees decreased by 74 or -60.66% compared to the previous year.

Employees

48

Change (1Y)

-74

Growth (1Y)

-60.66%

Revenue / Employee

$7,042

Profits / Employee

-$1,186,521

Market Cap

10.26M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2023	48	-74	-60.66%
Dec 31, 2022	122	33	37.08%
Dec 31, 2021	89	-	-

Related Stocks

Company Name	Employees
Turnstone Biologics	80
Mustang Bio	80
Biora Therapeutics	58
RedHill Biopharma	53
Jaguar Health	49
Brainstorm Cell Therapeutics	29
Dominari Holdings	28
BioRestorative Therapies	11

Employee Rankings

SNTI News

2 months ago - Senti Bio to Participate in Upcoming Investor Conferences - GlobeNewsWire
2 months ago - Senti Bio Announces Second Quarter 2024 Results and Reviews Recent Corporate and Pipeline Highlights - GlobeNewsWire
3 months ago - Senti Bio Announces Execution of Grant Award from California Institute for Regenerative Medicines (CIRM) for Clinical Development of SENTI-202 - GlobeNewsWire
3 months ago - Senti Bio Announces Reverse Stock Split - GlobeNewsWire
4 months ago - Senti Bio Awarded California Institute for Regenerative Medicines (CIRM) Grant for Clinical Development of Logic Gated CAR-NK Cell Therapy - GlobeNewsWire
6 months ago - Senti Bio Announces First Patient Dosed in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia - GlobeNewsWire
6 months ago - Senti Bio Announces First Quarter 2024 Results and Reviews Recent Corporate Highlights - GlobeNewsWire
6 months ago - Senti Bio Announces Publication of SENTI-202 Preclinical Data Demonstrating Potential of Logic-Gated CAR-NK Cell Therapy for the Treatment of Acute Myeloid Leukemia (AML) - GlobeNewsWire